Vertex Pharmaceuticals and Crinetics Pharmaceuticals announce a $10 billion acquisition, as the two companies detail a deal that expands Vertex’s drug pipeline. Vertex says the purchase adds Crinetics-developed therapies, including Palsonify and Atumelnant, and could increase Vertex’s annual revenue by up to $5 billion, based on the expected contribution from Crinetics’ products.
STAT News and The Wall Street Journal both report the headline terms of the transaction, including the $10 billion price. STAT also emphasizes that Crinetics’ portfolio includes a drug for a rare endocrine disorder, while noting broader biotech deal activity. The WSJ highlights the potential revenue impact of adding Crinetics’ pipeline assets.
Both sources frame the move as part of ongoing biotech mergers and acquisitions, with Vertex seeking to bolster its pipeline through the acquisition of Crinetics’ drug candidates and products. Details on timing, regulatory approvals, and financing terms are not included in the provided excerpts.
